Diagnostic Evaluation of Viral Persistence in Cervical Cancer

This study investigates the diagnostic potential of an electroacupuncture-based measurement method to detect viral persistence in patients with cervical cancer. Increasing evidence indicates that oncologic processes may be influenced by chronic viral activity, including persistent human papillomavirus (HPV) infection and, in some cases, secondary viral signatures such as SARS-CoV-2. Although HPV is the primary etiologic agent in cervical cancer, clinical observations suggest that long-term viral presence may contribute to variations in disease behavior, immune dysfunction, and treatment response.

The diagnostic method used in this study is based on measurement of electrical parameters at standardized acupuncture points. These points are functionally connected to organ systems involved in chronic viral disease. Changes in their electrical characteristics may reflect physiological responses associated with viral persistence. The technique has been previously developed and refined in clinical practice and has demonstrated reproducibility in identifying characteristic response patterns in patients with viral and post-viral conditions.

This study aims to evaluate whether measurable electrodiagnostic responses correlate with persistent viral signatures in cervical cancer patients. All participants undergo standardized diagnostic measurements performed under controlled conditions. The study does not involve therapeutic intervention, drug administration, or device implantation. Only diagnostic data are collected.

The primary objective is to assess whether this method can reliably identify patterns consistent with viral persistence. Secondary objectives include evaluating repeatability of measurements, describing characteristic profiles in this patient population, and assessing feasibility of integrating this diagnostic approach into clinical oncology settings.

This research is expected to contribute to a better understanding of viral involvement in cancer microenvironments and to support the development of non-invasive diagnostic tools for evaluating viral activity in oncologic patients.

Inclusion criteria

• Histologically confirmed cervical cancer (FIGO stage IIIA-IVA)
• Age ≥21 years
• ECOG performance status adequate for diagnostic procedures
• Adequate organ function
• Ability to provide informed consent

Exclusion criteria

• Poor renal function (elevated creatinine)
• Significant liver dysfunction (elevated bilirubin or liver enzymes)
• Severe cardiovascular or pulmonary disease
• Pregnancy or breastfeeding
• Severe mental illness or inability to provide informed consent
• Known non-compliance or substance abuse